tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

RemeGen Co., Ltd. Announces Successful H Shareholders Meeting with Key Resolutions Passed

Story Highlights
RemeGen Co., Ltd. Announces Successful H Shareholders Meeting with Key Resolutions Passed

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

RemeGen Co. Ltd. Class H ( (HK:9995) ) has issued an update.

RemeGen Co., Ltd. held its 2025 second class meeting of H shareholders, where key resolutions were passed, including changes to the company’s registered capital and amendments to its Articles of Association. The meeting saw participation from shareholders representing approximately 19.67% of the total issued H shares, with all resolutions receiving the required majority vote, indicating strong shareholder support for the proposed changes.

The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.

More about RemeGen Co. Ltd. Class H

RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the development and commercialization of innovative biologic drugs, particularly targeting oncology and autoimmune diseases.

Average Trading Volume: 11,694,103

Technical Sentiment Signal: Buy

Current Market Cap: HK$41.36B

For detailed information about 9995 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1